Inactivation of viruses in platelet and plasma products using a riboflavin‐and‐UV–based photochemical treatment

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Transfusion

• Publication date

  2015-07-01

• Fields of study

  Biology, Medicine, Chemistry, Environmental Science

• Identifiers
  DOI 10.1111/trf.13030PMID 25731607
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin

  2021cited by this paper
• Riboflavin and ultraviolet light for pathogen reduction of murine cytomegalovirus in blood products

  2015cited by this paper
• Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system

  2014cited by this paper
• Chemical and Biological Mechanisms of Pathogen Reduction Technologies

  2014cited by this paper
• Dynamic Spatiotemporal Trends of Dengue Transmission in the Asia-Pacific Region, 1955–2004

  2014cited by this paper
• Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system

  2013cited by this paper
• Natural selection of adaptive mutations in non-structural genes increases trans-encapsidation of hepatitis C virus replicons lacking envelope protein genes.

  2013cited by this paper
• Inactivation of Plasmodium spp. in plasma and platelet concentrates using riboflavin and ultraviolet light

  2013cited by this paper
• Fatal West Nile Virus Infection After Probable Transfusion-Associated Transmission — Colorado, 2012

  2013cited by this paper
• Dengue infections in travellers

  2012cited by this paper
• Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services

  2012cited by this paper
• International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009

  2012cited by this paper
• Evaluation of Pathogen Reduction Systems to Inactivate Dengue and Chikungunya Viruses in Apheresis Platelets Suspended in Plasma

  2012cited by this paper
• Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms

  2011cited by this paper
• West Nile virus infection transmitted by granulocyte transfusion.

  2011cited by this paper
• The cost‐effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model

  2010cited by this paper
• Transfusion‐transmitted arboviruses

  2010cited by this paper
• Defining “adequate” pathogen reduction performance for transfused blood components

  2010cited by this paper
• HIV transmission through transfusion --- Missouri and Colorado, 2008.

  2010cited by this paper
• Update on the global spread of dengue.

  2010cited by this paper
• Role of N-Linked Glycans in the Functions of Hepatitis C Virus Envelope Proteins Incorporated into Infectious Virions

  2010cited by this paper
• A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns

  2009cited by this paper
• Comparison of the analytical and operational performance of two viral nucleic acid test blood screening systems: Procleix Tigris and cobas s 201

  2009cited by this paper
• Committee for Proprietary Medicinal Products (CPMP)

  2009cited by this paper
• Evaluation of the Mirasol platelet reduction technology system against Babesia microti in apheresis platelets and plasma

  2009cited by this paper
• Parvovirus B19 infection in the immunocompromised host.

  2007cited by this paper
• Two Chikungunya Isolates from the Outbreak of La Reunion (Indian Ocean) Exhibit Different Patterns of Infection in the Mosquito, Aedes albopictus

  2007cited by this paper
• Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light.

  2007cited by this paper
• Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model

  2007cited by this paper
• Transfusion‐associated transmission of West Nile virus, United States 2003 through 2005

  2006cited by this paper
• Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light

  2006cited by this paper
• Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light

  2004cited by this paper
• Detection of West Nile virus in blood donations--United States, 2003.

  2003cited by this paper
• The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology

  2001cited by this paper
• Guide to the Preparation, Use and Quality Assurance of Blood Components

  1999cited by this paper
• Cytopenia caused by parvovirus in an adult ALL patient.

  1994cited by this paper
• Growth of human hepatoma cells lines with differentiated functions in chemically defined medium.

  1982cited by this paper

• Material limitations in blood storage bags: A critical review of packaging-induced deterioration

  2026cites this paper
• Near-UVA Radiation at 405 nm: Germicidal Effect With and Without Sub-Lethal Conditions on Gram-Positive and Gram-Negative Bacteria

  2026cites this paper
• Pathogeninaktivierungssysteme für Thrombozytenkonzentrate – Aktualisierung 2024

  2026cites this paper
• La Crosse Virus: A Comprehensive Review of Its Emerging Public Health Importance

  2025cites this paper
• Evaluation of riboflavin concentrations and light intensities on bacteria reduction in platelets using visible light.

  2024cites this paper
• Antibody Aggregation: A Problem Within the Biopharmaceutical Industry and Its Role in AL Amyloidosis Disease

  2024cites this paper
• Pathogen reduction of monkeypox virus in plasma and whole blood using riboflavin and UV light

  2023cites this paper
• The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial

  2022cites this paper
• A minimally manipulated preservation and virus inactivation method for amnion/chorion

  2022cites this paper
• Identification of key metabolic pathways reprogrammed by BmNPV in silkworm Bombyx mori.

  2022cites this paper
• SARS-CoV-2 variants inactivation of plasma units using a riboflavin and ultraviolet light-based photochemical treatment

  2022cites this paper
• Pathogen Reduction for Platelets—A Review of Recent Implementation Strategies

  2022cites this paper
• Platelet Transfusion—Insights from Current Practice to Future Development

  2021cites this paper
• Pathogen Reduction Technology for blood component: A promising solution for prevention of emerging infectious disease and bacterial contamination in blood transfusion services

  2021cites this paper
• Topical Oral and Intranasal Antiviral Agents for Coronavirus Disease 2019 (COVID-19).

  2021cites this paper
• In vitro characteristics and in vivo platelet quality of whole blood treated with riboflavin and UVA/UVB light and stored for 24 hours at room temperature

  2021influential citation
• Damage Control Resuscitation: Identification and Treatment of Life-Threatening Hemorrhage

  2020influential citation
• Inactivation of bacteria in plasma by photosensitizers benzophenone and vitamins K3, B1 and B6 with UV A light irradiation.

  2020cites this paper
• Synergistic bactericidal effects of pairs of photosensitizer molecules activated by ultraviolet A light against bacteria in plasma

  2020cites this paper
• Effects of riboflavin and ultraviolet light treatment on pathogen reduction and platelets

  2020cites this paper
• Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light‐based photochemical treatment

  2020cites this paper
• The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates

  2019cites this paper
• A comprehensive proteomics study on platelet concentrates: Platelet proteome, storage time and Mirasol pathogen reduction technology

  2019cites this paper
• Evaluation of the effectiveness of the SurePure Turbulator ultraviolet-C irradiation equipment on inactivation of different enveloped and non-enveloped viruses inoculated in commercially collected liquid animal plasma

  2019influential citation
• A double‐virally‐inactivated (Intercept–solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells

  2019cites this paper
• The long and winding road to pathogen reduction of platelets, red blood cells and whole blood

  2019cites this paper
• Dried Plasma

  2019cites this paper
• Pathogen reduction combined with rapid diagnostic tests to reduce the risk of transfusion‐transmitted infections in Uganda

  2018cites this paper
• Effectiveness of a flow-based device using riboflavin photochemistry in damaging blood-borne viral nucleic acids.

  2018cites this paper
• Ultraviolet-Based Pathogen Inactivation Systems: Untangling the Molecular Targets Activated in Platelets

  2018cites this paper
• Quest for the holy grail: pathogen reduction in low‐income countries

  2018influential citation
• Vitamin B2 and Innovations in Improving Blood Safety

  2018cites this paper
• Ultraviolet C light efficiently inactivates nonenveloped hepatitis A virus and feline calicivirus in platelet concentrates

  2018cites this paper
• Pathogen-Inaktivierungssysteme für Thrombozytenkonzentrate

  2018cites this paper
• Using pathogen inactivation treatment to study the stability of platelet messenger RNA

  2017cites this paper
• Inactivation of Middle East respiratory syndrome coronavirus (MERS‐CoV) in plasma products using a riboflavin‐based and ultraviolet light‐based photochemical treatment

  2016cites this paper
• A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial

  2016cites this paper
• Riboflavin‐ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells

  2016cites this paper
• Riboflavin and ultraviolet light: impact on dengue virus infectivity

  2016cites this paper
• Transfusion Reactions.

  2016cites this paper
• Riboflavin and ultraviolet illumination affects selected platelet mRNA transcript amounts differently

  2016cites this paper
• Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days.

  2016cites this paper
• Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro

  2016cites this paper
• Riboflavin and UV light treatment of platelets: a protective effect of platelet additive solution?

  2015cites this paper
• ПРОФИЛАКТИКА ПОСТТРАНСФУЗИОННОГО ВИРУСНОГО ГЕПАТИТА С ПРИ ПЕРЕЛИВАНИИ ДОНОРСКОЙ КРОВИ И ЕЕ КОМПОНЕНТОВ

  2015cites this paper
• Humanes Cytomegalievirus (HCMV)

  2010cites this paper